Biogen will also make these resources available through a link on their Zurzuvae (zuranolone) patient website to help support women with PPD symptoms, in another example of the trend for pharma ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology company specializing in developing and delivering innovative therapies.

SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Late last week, Biogen made an unsolicited offer to buy one of its partners, brain drug developer Sage Therapeutics. The two biotechnology companies have worked together over the past four years ...

Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

In a report released today, Evan Seigerman from BMO Capital downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of $164.00. Discover top-rated stocks from highly ranked ...

Anthony Noto FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with ...